Author: Xu, Yingying; Yuen, Pak-Wai; Lam, Jenny Ka-Wing
Title: Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives Cord-id: 0bma2749 Document date: 2014_7_10
ID: 0bma2749
Snippet: Intranasal delivery of DNA vaccines has become a popular research area recently. It offers some distinguished advantages over parenteral and other routes of vaccine administration. Nasal mucosa as site of vaccine administration can stimulate respiratory mucosal immunity by interacting with the nasopharyngeal-associated lymphoid tissues (NALT). Different kinds of DNA vaccines are investigated to provide protection against respiratory infectious diseases including tuberculosis, coronavirus, influe
Document: Intranasal delivery of DNA vaccines has become a popular research area recently. It offers some distinguished advantages over parenteral and other routes of vaccine administration. Nasal mucosa as site of vaccine administration can stimulate respiratory mucosal immunity by interacting with the nasopharyngeal-associated lymphoid tissues (NALT). Different kinds of DNA vaccines are investigated to provide protection against respiratory infectious diseases including tuberculosis, coronavirus, influenza and respiratory syncytial virus (RSV) etc. DNA vaccines have several attractive development potential, such as producing cross-protection towards different virus subtypes, enabling the possibility of mass manufacture in a relatively short time and a better safety profile. The biggest obstacle to DNA vaccines is low immunogenicity. One of the approaches to enhance the efficacy of DNA vaccine is to improve DNA delivery efficiency. This review provides insight on the development of intranasal DNA vaccine for respiratory infections, with special attention paid to the strategies to improve the delivery of DNA vaccines using non-viral delivery agents.
Search related documents:
Co phrase search for related documents- ability target and action mechanism: 1, 2, 3, 4
- ability target and activate cell: 1
- acceptable profile and acid fatty phosphate: 1
- acceptable profile and acid fatty phosphate group: 1
- acceptable profile and action mechanism: 1
- accordingly control and acute ards respiratory distress syndrome: 1
- acid fatty phosphate and action mechanism: 1
- acid fatty phosphate group and action mechanism: 1
- acids delivery and action mechanism: 1
- acids delivery and activation accumulation: 1
- acids delivery and acute rsv infection respiratory syncytial virus: 1
- action mechanism and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- action mechanism and acute ards respiratory distress syndrome cause: 1, 2, 3, 4
- action mechanism and acute effect: 1, 2, 3, 4, 5
- action mechanism and acute sars cov respiratory syndrome cov: 1
- action mechanism and adaptive immune system: 1
- activate cell and acute ards respiratory distress syndrome: 1
- activate cell and acute effect: 1
- activate cell and acute sars cov respiratory syndrome cov: 1
Co phrase search for related documents, hyperlinks ordered by date